Thrombosis with Thrombocytopenia Syndrome (TTS), also known as Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), is a rare but serious medical condition that gained attention during the COVID-19 pandemic due to its association with certain adenoviral vector-based COVID-19 vaccines, such as AstraZeneca (Vaxzevria) and Johnson & Johnson (Janssen). At healthcare nt sickcare, an ISO 9001:2015 certified online medical laboratory in Pune, India, we provide testing services to support health monitoring, including for conditions like TTS, through our NABL-certified partner labs. This article explains TTS, its symptoms, and how we can assist with testing, while emphasizing that we do not provide medical advice or diagnoses.
What is Thrombosis with Thrombocytopenia Syndrome (TTS)?
TTS is characterized by blood clots (thrombosis) combined with low platelet counts (thrombocytopenia). Platelets are essential for blood clotting, and a low count can lead to bleeding risks, while clots can block blood vessels, causing serious complications. TTS was identified as a rare side effect of adenoviral vector COVID-19 vaccines, primarily occurring 4–42 days after vaccination.
Link to COVID-19 Vaccines
During the COVID-19 pandemic, TTS was reported in a few individuals receiving the AstraZeneca or Johnson & Johnson vaccines. The condition is thought to involve an immune response triggering platelet-activating antibodies against platelet factor 4 (PF4), similar to heparin-induced thrombocytopenia (HIT), though without prior heparin exposure. The AstraZeneca vaccine is no longer used in Australia, and no further TTS cases are expected there.
Prevalence and Risk
TTS is extremely rare, with an estimated incidence of 2–3 cases per 100,000 vaccinated individuals for AstraZeneca’s first dose, and even lower for Johnson & Johnson (approximately 3.53 per million doses in the US). Women under 60, particularly those under 50, appeared to experience more severe outcomes, though no specific risk factors have been confirmed.
Symptoms of TTS
Recognizing TTS symptoms early is critical for timely medical intervention. Symptoms typically appear 4–42 days post-vaccination and may include:
Severe or persistent headaches, especially with vision changes or neurological symptoms (e.g., cerebral venous sinus thrombosis, CVST).
Abdominal pain, nausea, or vomiting (e.g., splanchnic vein thrombosis).
Leg pain, swelling, or shortness of breath (e.g., deep vein thrombosis or pulmonary embolism).
Bleeding, petechiae (tiny blood spots under the skin), or bruising.
Mild symptoms like fever or fatigue in the first 48 hours post-vaccination are common and not indicative of TTS. If severe symptoms persist, consult a healthcare professional immediately.
TTS and Covishield in India
Covishield, a version of AstraZeneca’s vaccine, was a cornerstone of India’s vaccination campaign. In April 2021, global reports linked adenoviral vector vaccines like Covishield to TTS, prompting scrutiny. AstraZeneca acknowledged in 2024 that Covishield can, in very rare cases, cause TTS, with an estimated risk of 0.5–6.8 cases per 100,000 doses, primarily after the first dose. In India, specific TTS case data is limited, with only 21 potential cases reported by 2024, none definitively confirmed per WHO criteria. This reflects a rate of approximately 1–10 cases per million doses, underscoring its rarity given India’s 1.78 billion vaccine doses administered.
India continued Covishield use, with the Ministry of Health and Family Welfare and the National Technical Advisory Group on Immunization (NTAGI) monitoring adverse events. The Therapeutic Goods Administration (TGA) and WHO emphasized that vaccine benefits outweigh TTS risks, especially during high COVID-19 transmission periods. No widespread suspension occurred in India, unlike some countries (e.g., Denmark, Norway), though warnings were added to Covishield’s labelling.
Diagnosis of TTS
Diagnosing TTS involves blood tests and imaging:
Tests for TTS
Platelet Count: Detects thrombocytopenia (<150,000 per microlitre).
D-dimer Test: Identifies elevated levels (>4,000 FEU or >4 times normal).
Fibrinogen Test: Assesses clotting properties.
Anti-PF4 ELISA: Confirms platelet-activating antibodies (available at specialized labs).
Imaging (e.g., CT scans) for clots is arranged by healthcare providers, not our service.
healthcare nt sickcare can facilitate blood tests like platelet counts and D-dimer through our NABL-certified labs. Book tests via our services page.
Differential Diagnosis
TTS must be distinguished from other conditions like:
Heparin-Induced Thrombocytopenia (HIT): Similar mechanism, but linked to heparin exposure.
Thrombotic Thrombocytopenic Purpura (TTP): Caused by ADAMTS13 deficiency, not anti-PF4 antibodies.
Role of Lab Testing
Laboratory tests are crucial for identifying low platelet counts and elevated D-dimer levels, which are hallmarks of TTS. Our services include platelet count tests and other blood panels to support your healthcare provider’s diagnosis. Results are delivered in 6–72 hours via email or WhatsApp
Data Limitations
India’s adverse event reporting system (AEFI) recorded minimal confirmed TTS cases, possibly due to underdiagnoses or underreporting. The lack of widespread PF4 antibody testing and limited post-vaccination surveillance in 2021–2022 may have obscured the true incidence. healthcare nt sickcare supports enhanced monitoring through accessible testing.
Data Privacy
Your test data is handled securely per our Privacy Policy and the Digital Personal Data Protection Act, 2023, ensuring confidentiality and compliance.
Watch Our Video
This video explains, how to effectively use a digital pulse oximeter, while clarifying our role as a testing provider, not a medical advisor.
What is TTS, and why is it linked to COVID-19 vaccines?
TTS is a rare condition involving blood clots and low platelet counts, associated with adenoviral vector COVID-19 vaccines like AstraZeneca and Johnson & Johnson. It’s triggered by an immune response producing anti-PF4 antibodies, resembling HIT.
Diagnosis involves blood tests (platelet count, D-dimer, anti-PF4 ELISA) and imaging (e.g., CT scans). healthcare nt sickcare offers relevant blood tests through NABL-certified labs. Book at healthcarentsickcare.com/collections/all.
Can healthcare nt sickcare interpret my TTS test results?
No, we provide test results only, not medical advice or interpretation. Consult a licensed physician for diagnosis and treatment. See our No Medical Advice page.
How soon will I get my test results?
Results are delivered securely in 6–72 hours via email or WhatsApp, depending on the test.
Is TTS still a concern in 2025?
Since the AstraZeneca vaccine is no longer used in some countries (e.g., Australia), TTS cases have decreased. However, testing remains relevant for monitoring similar conditions.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. healthcare nt sickcare provides laboratory testing and reporting services, not medical consultations. Always consult a licensed healthcare professional for medical guidance. Test results are handled per our Privacy Policy and the Digital Personal Data Protection Act, 2023. We are not liable for actions taken based on this information.